Abstract 2352P
Background
ASCC is a relatively rare malignancy. Several studies reported favourable prognosis in Female to Male patients (pts).Our work aims to identify and quantify sex-based differences in cancer-associated genomic alterations to better inform future precision medicine initiatives and provide insights on potential different survival based on sex.
Methods
A cohort of 1,380 ASCC pts (952 F,428 M) underwent genomic profiling on tissue biopsies using FoundationOne®/FoundationOne®CDx assays, to examine key differences in mutational patterns based on sex and HPV status.
Results
HPV-16 was prevalent in F while HPV-6 in M. PD-L1 expression: over 70% positive (1%), ∼20% high (50%) with similar rates in HPV+ vs HPV- (74.5% vs 63.9%; p=0.16) and sex (F:74% vs M:70.4%; p=0.80). TMB-High (10+mutations/Mb) was found in ∼18% without significant differences by sex (p=0.80); a slightly elevated rate was seen in HPV+ vs HPV- (18.4% vs 14.0%; p=0.16); 34% had PIK3CA alterations (37.1% in HPV+ vs.16.8% in HPV- ; p<.01 with similar rates by sex F:37.1% vs 20.8%; M:37.1% vs 13.3%); in contrast higher prevalence in HPV- vs HPV+ resulted to TP53 (44.9% vs 5.6% p<.01), TERT(31.3% vs 2.7% p<.01), CDNK2A (29% vs 2.9%p<.01), CDNK2B (11.7% vs 1.6% p<.01) and NOTCH1 (14.5% vs 5.1% p<.01); F had higher rates of alterations in PTEN (15.3% vs 8.4%p<.01) ,KMT2D (21% vs 13.1%, p<.01), CBFB (3.3% vs 0.2%; p<.01) and CREBBP (5.4 vs 2.6%; p=0.06),whereas M showed higher rates of alterations in TERT(15.2 vs 3.5% p<.01), TP53 (20.3% vs 7.8% p<.01),CDKN2A (14% vs 3.8%p<.01),CDKN2B (5.4% vs 2.2% p=.02), MYC (4.2% vs 1.6% p=.03) as well as amplifications on 11q13 such as CCND1(7%vs3.2%p=0.02), FGF19 (7%vs3.3%p=0.02), FGF3(7.2%vs3.6%,p=0.02), FGF4 (7% vs 3.5% p=0.02). BRCA1 and BRCA2 mutations were in 5% pts with mild M predominance (7% vs 4%) regardless HPV expression.
Conclusions
The higher incidence of HPV positivity in F compared to M remains the main hypothesis to justify the better prognosis of ASCC in women. A large proportion of PD-L1+ and TMB-High (∼70%), PIK3CA alterations (∼30%) and BRCA1/2 gene alteration (5%) may predict response to possible new therapeutic approaches for pts with ASCC like immunotherapy, targeted tyrosine kinase inhibitors, platinum chemotherapy and PARP inhibitors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2222P - Frequent TERT gains in metastatic papillary thyroid carcinoma
Presenter: Sara Gil
Session: Poster session 16
2223P - Next-generation sequencing enables identification of RET rearrangements in papillary thyroid cancer
Presenter: Sergi Clavé
Session: Poster session 16
2224P - Identifying prognostic factors in patients with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) treated with tyrosine kinase inhibitors (TKI): Data from REGETNE registry
Presenter: Maria Victoria San Roman Gil
Session: Poster session 16
2225P - FOX1 (rs965513), NKX2-1 (rs944289) and BRAF (V600E) gene mutations and their role in development of papillary thyroid cancer
Presenter: Darko Katalinic
Session: Poster session 16
2226P - Survival benefit of radioiodine therapy (RAI) in papillary thyroid cancer variants (PTCV): A SEER analysis
Presenter: Sakhr Alshwayyat
Session: Poster session 16
2227P - The efficacy and safety of lenvatinib in neoadjuvant therapy in patients with locally advanced thyroid cancer: A single-arm phase II clinical trial
Presenter: Jianhong Yu
Session: Poster session 16
2228P - Long-term clinical outcomes of Lenvatinib in patients with differentiated thyroid cancer: Results from the real-world practice of a single institution
Presenter: Ryutaro Onaga
Session: Poster session 16
2229P - Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001
Presenter: Lori Wirth
Session: Poster session 16
2323P - Multi-omic spatial phenotyping of the NSCLC tumour microenvironment for the development of a spatial score associated with immunotherapy resistance
Presenter: Arutha Kulasinghe
Session: Poster session 16
2324P - Trametinib and PD-1 combined blockade impairs tumor growth and improves survival of KRAS-mutant lung cancer through Id1 downregulation
Presenter: Ander Puyalto
Session: Poster session 16